Sunday at the ASCO annual meeting

There were a number of significant prostate cancer presentations today, and while none of them were “game changing” (for a variety of reasons), they are certainly worthy of notice. … READ MORE …

More data to come at ASCO in June

We commented earlier today on the positive data about tasquinimod that will be presented at the ASCO annual meeting. Negative data will unfortunately be presented on other drugs, but not everything is doom and gloom. … READ MORE …

The continuing search for impactful chemotherapies in HRPC

In March this year it was announced that the combination of bevacizumab (Avastin) with docetaxel and prednisone had no benficial impact (in a large Phase III trial) on the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. There are, naturally, hopes that the outcome might be different if one adds a third drug into the mix. … READ MORE …

Avastin does NOT extend survival of patients with HRPC

The pharmaceutical company Roche announced this morning that the combination of bevacizumab (Avastin) with docetaxel and prednisone does not extend the overall survival of men with hormone-refractory prostate cancer (HRPC) compared to docetaxel + prednisone alone. … READ MORE …

AUA report and update no. 6: Monday, April 27, 2009

We learned a few other interesting tidbits during a variety of sessions and conversations today. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers